Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting [beta]2agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation. Adults with uncontrolled persistent asthma who are receiving medium-to-high-dose inhaled corticosteroids plus a long-acting β...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2016-07, Vol.388 (10039), p.31
Main Authors: Wenzel, Sally, Castro, Mario, Corren, Jonathan, Maspero, Jorge, Wang, Lin, Zhang, Bingzhi, Pirozzi, Gianluca, Sutherland, E Rand, Evans, Robert R, Joish, Vijay N, Eckert, Laurent, Graham, Neil M H, Stahl, Neil, Yancopoulos, George D, Louis-Tisserand, Mariana, Teper, Ariel
Format: Article
Language:English
Subjects:
Asthma
Clinical trials
Comorbidity
Cytokines
Drug therapy
Steroids
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 10039
container_start_page 31
container_title The Lancet (British edition)
container_volume 388
creator Wenzel, Sally
Castro, Mario
Corren, Jonathan
Maspero, Jorge
Wang, Lin
Zhang, Bingzhi
Pirozzi, Gianluca
Sutherland, E Rand
Evans, Robert R
Joish, Vijay N
Eckert, Laurent
Graham, Neil M H
Stahl, Neil
Yancopoulos, George D
Louis-Tisserand, Mariana
Teper, Ariel
description Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation. Adults with uncontrolled persistent asthma who are receiving medium-to-high-dose inhaled corticosteroids plus a long-acting β2agonist require additional treatment options as add-on therapy. We aimed to assess the efficacy and safety of dupilumab as add-on therapy in patients with uncontrolled persistent asthma on medium-to-high-dose inhaled corticosteroids plus a long-acting β2agonist, irrespective of baseline eosinophil count. Methods We did this randomised, double-blind, placebo-controlled, parallel-group, pivotal phase 2b clinical trial at 174 study sites across 16 countries or regions. Adults (aged >=18 years) with an asthma diagnosis for 12 months or more based on the Global Initiative for Asthma 2009 Guidelines receiving treatment with medium-to-high-dose inhaled corticosteroids plus a long-acting β2agonist were eligible for participation. Patients were randomly assigned (1:1:1:1:1) to receive subcutaneous dupilumab 200 mg or 300 mg every 2 weeks or every 4 weeks, or placebo, over a 24-week period. The primary endpoint was change from baseline at week 12 in forced expiratory volume in 1 s (FEV1in L) in patients with baseline blood eosinophil counts of at least 300 eosinophils per μL assessed in the intention-to-treat population. Safety outcomes were assessed in all patients that received at least one dose or part of a dose of study drug. This trial is registered atClinicalTrials.gov, numberNCT01854047, and with the EU Clinical Trials Register, EudraCT number 2013-000856-16. Findings 769 patients (158 in the placebo group and 611 in the dupilumab groups) received at least one dose of study drug. In the subgroup with at least 300 eosinophils per μL, the greatest increases (200 mg every 2 weeks, p=0·0008; 300 mg every 2 weeks, p=0·0063) in FEV1compared with placebo were observed at week 12 with doses every 2 weeks in the 300 mg group (mean change 0·39 L [SE 0·05]; mean difference 0·21 [95% CI 0·06-0·36; p=0·0063]) and in the 200 mg group (mean change 0·43 L [SE 0·05]; mean difference 0·26 [0·11-0·40; p=0·0008]) compared with placebo (0·18 L [SE 0·05]). Similar significant increases were observed in the overall population and in the fewer than 300 eosinophils per μL subgroup (overall population: 200 mg every 2 weeks, p
doi_str_mv 10.1016/S0140-6736(16)30307-5
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1802783675</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4113367381</sourcerecordid><originalsourceid>FETCH-proquest_journals_18027836753</originalsourceid><addsrcrecordid>eNqNjktLxDAQx4MouD4-gjDgRQ_RdPtavPrAux4EkWXapO0saaY2ibJf3ZNZEPHoaWD-r58QZ5m6ylRWXT-prFCyqvPqIqsuc5WrWpZ7YpEVdSHLon7ZF4tfy6E48n6jlCoqVS7E112cyMYRGzBdRy22W0CnwWNnwhbIAepog4dPCgNE17ILM1trNExm9uSDcQHQh2FE0MZPFAxEb4A7GI2mOMrAcqB-kJrTm9yAu3DLc6CWU3xm0h4mGz0gWHa9xDaQ6-G1MQHfltizSzM3SZ0TGY_kU15zbKyRjaUEO1lsTcPyLxx9cEAL04BpddnAbl2mgn5XHWZCeyIOOrTenP7cY3H-cP98-yinmd-j8WG94Ti7JK2zlVrWq7yqy_x_rm96HobP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1802783675</pqid></control><display><type>article</type><title>Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting [beta]2agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial</title><source>Elsevier</source><creator>Wenzel, Sally ; Castro, Mario ; Corren, Jonathan ; Maspero, Jorge ; Wang, Lin ; Zhang, Bingzhi ; Pirozzi, Gianluca ; Sutherland, E Rand ; Evans, Robert R ; Joish, Vijay N ; Eckert, Laurent ; Graham, Neil M H ; Stahl, Neil ; Yancopoulos, George D ; Louis-Tisserand, Mariana ; Teper, Ariel</creator><creatorcontrib>Wenzel, Sally ; Castro, Mario ; Corren, Jonathan ; Maspero, Jorge ; Wang, Lin ; Zhang, Bingzhi ; Pirozzi, Gianluca ; Sutherland, E Rand ; Evans, Robert R ; Joish, Vijay N ; Eckert, Laurent ; Graham, Neil M H ; Stahl, Neil ; Yancopoulos, George D ; Louis-Tisserand, Mariana ; Teper, Ariel</creatorcontrib><description>Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation. Adults with uncontrolled persistent asthma who are receiving medium-to-high-dose inhaled corticosteroids plus a long-acting β2agonist require additional treatment options as add-on therapy. We aimed to assess the efficacy and safety of dupilumab as add-on therapy in patients with uncontrolled persistent asthma on medium-to-high-dose inhaled corticosteroids plus a long-acting β2agonist, irrespective of baseline eosinophil count. Methods We did this randomised, double-blind, placebo-controlled, parallel-group, pivotal phase 2b clinical trial at 174 study sites across 16 countries or regions. Adults (aged &gt;=18 years) with an asthma diagnosis for 12 months or more based on the Global Initiative for Asthma 2009 Guidelines receiving treatment with medium-to-high-dose inhaled corticosteroids plus a long-acting β2agonist were eligible for participation. Patients were randomly assigned (1:1:1:1:1) to receive subcutaneous dupilumab 200 mg or 300 mg every 2 weeks or every 4 weeks, or placebo, over a 24-week period. The primary endpoint was change from baseline at week 12 in forced expiratory volume in 1 s (FEV1in L) in patients with baseline blood eosinophil counts of at least 300 eosinophils per μL assessed in the intention-to-treat population. Safety outcomes were assessed in all patients that received at least one dose or part of a dose of study drug. This trial is registered atClinicalTrials.gov, numberNCT01854047, and with the EU Clinical Trials Register, EudraCT number 2013-000856-16. Findings 769 patients (158 in the placebo group and 611 in the dupilumab groups) received at least one dose of study drug. In the subgroup with at least 300 eosinophils per μL, the greatest increases (200 mg every 2 weeks, p=0·0008; 300 mg every 2 weeks, p=0·0063) in FEV1compared with placebo were observed at week 12 with doses every 2 weeks in the 300 mg group (mean change 0·39 L [SE 0·05]; mean difference 0·21 [95% CI 0·06-0·36; p=0·0063]) and in the 200 mg group (mean change 0·43 L [SE 0·05]; mean difference 0·26 [0·11-0·40; p=0·0008]) compared with placebo (0·18 L [SE 0·05]). Similar significant increases were observed in the overall population and in the fewer than 300 eosinophils per μL subgroup (overall population: 200 mg every 2 weeks, p&lt;0·0001; 300 mg every 2 weeks, p&lt;0·0001; &lt;300 eosinophils per μL: 200 mg every 2 weeks, p=0·0034; 300 mg every 2 weeks, p=0·0086), and were maintained to week 24. Likewise, dupilumab every 2 weeks produced the greatest reductions in annualised rates of exacerbation in the overall population (70-70·5%), the subgroup with at least 300 eosinophils per μL (71·2-80·7%), and the subgroup with fewer than 300 eosinophils per μL (59·9-67·6%). The most common adverse events with dupilumab compared with placebo were upper respiratory tract infections (33-41%vs35%) and injection-site reactions (13-26%vs13%). Interpretation Dupilumab increased lung function and reduced severe exacerbations in patients with uncontrolled persistent asthma irrespective of baseline eosinophil count and had a favourable safety profile, and hence in addition to inhaled corticosteroids plus long-acting β2-agonist therapy could improve the lives of patients with uncontrolled persistent asthma compared with standard therapy alone. Funding Sanofi-Genzyme and Regeneron Pharmaceuticals.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(16)30307-5</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Limited</publisher><subject>Asthma ; Clinical trials ; Comorbidity ; Cytokines ; Drug therapy ; Steroids</subject><ispartof>The Lancet (British edition), 2016-07, Vol.388 (10039), p.31</ispartof><rights>Copyright Elsevier Limited Jul 2, 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids></links><search><creatorcontrib>Wenzel, Sally</creatorcontrib><creatorcontrib>Castro, Mario</creatorcontrib><creatorcontrib>Corren, Jonathan</creatorcontrib><creatorcontrib>Maspero, Jorge</creatorcontrib><creatorcontrib>Wang, Lin</creatorcontrib><creatorcontrib>Zhang, Bingzhi</creatorcontrib><creatorcontrib>Pirozzi, Gianluca</creatorcontrib><creatorcontrib>Sutherland, E Rand</creatorcontrib><creatorcontrib>Evans, Robert R</creatorcontrib><creatorcontrib>Joish, Vijay N</creatorcontrib><creatorcontrib>Eckert, Laurent</creatorcontrib><creatorcontrib>Graham, Neil M H</creatorcontrib><creatorcontrib>Stahl, Neil</creatorcontrib><creatorcontrib>Yancopoulos, George D</creatorcontrib><creatorcontrib>Louis-Tisserand, Mariana</creatorcontrib><creatorcontrib>Teper, Ariel</creatorcontrib><title>Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting [beta]2agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial</title><title>The Lancet (British edition)</title><description>Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation. Adults with uncontrolled persistent asthma who are receiving medium-to-high-dose inhaled corticosteroids plus a long-acting β2agonist require additional treatment options as add-on therapy. We aimed to assess the efficacy and safety of dupilumab as add-on therapy in patients with uncontrolled persistent asthma on medium-to-high-dose inhaled corticosteroids plus a long-acting β2agonist, irrespective of baseline eosinophil count. Methods We did this randomised, double-blind, placebo-controlled, parallel-group, pivotal phase 2b clinical trial at 174 study sites across 16 countries or regions. Adults (aged &gt;=18 years) with an asthma diagnosis for 12 months or more based on the Global Initiative for Asthma 2009 Guidelines receiving treatment with medium-to-high-dose inhaled corticosteroids plus a long-acting β2agonist were eligible for participation. Patients were randomly assigned (1:1:1:1:1) to receive subcutaneous dupilumab 200 mg or 300 mg every 2 weeks or every 4 weeks, or placebo, over a 24-week period. The primary endpoint was change from baseline at week 12 in forced expiratory volume in 1 s (FEV1in L) in patients with baseline blood eosinophil counts of at least 300 eosinophils per μL assessed in the intention-to-treat population. Safety outcomes were assessed in all patients that received at least one dose or part of a dose of study drug. This trial is registered atClinicalTrials.gov, numberNCT01854047, and with the EU Clinical Trials Register, EudraCT number 2013-000856-16. Findings 769 patients (158 in the placebo group and 611 in the dupilumab groups) received at least one dose of study drug. In the subgroup with at least 300 eosinophils per μL, the greatest increases (200 mg every 2 weeks, p=0·0008; 300 mg every 2 weeks, p=0·0063) in FEV1compared with placebo were observed at week 12 with doses every 2 weeks in the 300 mg group (mean change 0·39 L [SE 0·05]; mean difference 0·21 [95% CI 0·06-0·36; p=0·0063]) and in the 200 mg group (mean change 0·43 L [SE 0·05]; mean difference 0·26 [0·11-0·40; p=0·0008]) compared with placebo (0·18 L [SE 0·05]). Similar significant increases were observed in the overall population and in the fewer than 300 eosinophils per μL subgroup (overall population: 200 mg every 2 weeks, p&lt;0·0001; 300 mg every 2 weeks, p&lt;0·0001; &lt;300 eosinophils per μL: 200 mg every 2 weeks, p=0·0034; 300 mg every 2 weeks, p=0·0086), and were maintained to week 24. Likewise, dupilumab every 2 weeks produced the greatest reductions in annualised rates of exacerbation in the overall population (70-70·5%), the subgroup with at least 300 eosinophils per μL (71·2-80·7%), and the subgroup with fewer than 300 eosinophils per μL (59·9-67·6%). The most common adverse events with dupilumab compared with placebo were upper respiratory tract infections (33-41%vs35%) and injection-site reactions (13-26%vs13%). Interpretation Dupilumab increased lung function and reduced severe exacerbations in patients with uncontrolled persistent asthma irrespective of baseline eosinophil count and had a favourable safety profile, and hence in addition to inhaled corticosteroids plus long-acting β2-agonist therapy could improve the lives of patients with uncontrolled persistent asthma compared with standard therapy alone. Funding Sanofi-Genzyme and Regeneron Pharmaceuticals.</description><subject>Asthma</subject><subject>Clinical trials</subject><subject>Comorbidity</subject><subject>Cytokines</subject><subject>Drug therapy</subject><subject>Steroids</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqNjktLxDAQx4MouD4-gjDgRQ_RdPtavPrAux4EkWXapO0saaY2ibJf3ZNZEPHoaWD-r58QZ5m6ylRWXT-prFCyqvPqIqsuc5WrWpZ7YpEVdSHLon7ZF4tfy6E48n6jlCoqVS7E112cyMYRGzBdRy22W0CnwWNnwhbIAepog4dPCgNE17ILM1trNExm9uSDcQHQh2FE0MZPFAxEb4A7GI2mOMrAcqB-kJrTm9yAu3DLc6CWU3xm0h4mGz0gWHa9xDaQ6-G1MQHfltizSzM3SZ0TGY_kU15zbKyRjaUEO1lsTcPyLxx9cEAL04BpddnAbl2mgn5XHWZCeyIOOrTenP7cY3H-cP98-yinmd-j8WG94Ti7JK2zlVrWq7yqy_x_rm96HobP</recordid><startdate>20160702</startdate><enddate>20160702</enddate><creator>Wenzel, Sally</creator><creator>Castro, Mario</creator><creator>Corren, Jonathan</creator><creator>Maspero, Jorge</creator><creator>Wang, Lin</creator><creator>Zhang, Bingzhi</creator><creator>Pirozzi, Gianluca</creator><creator>Sutherland, E Rand</creator><creator>Evans, Robert R</creator><creator>Joish, Vijay N</creator><creator>Eckert, Laurent</creator><creator>Graham, Neil M H</creator><creator>Stahl, Neil</creator><creator>Yancopoulos, George D</creator><creator>Louis-Tisserand, Mariana</creator><creator>Teper, Ariel</creator><general>Elsevier Limited</general><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20160702</creationdate><title>Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting [beta]2agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial</title><author>Wenzel, Sally ; Castro, Mario ; Corren, Jonathan ; Maspero, Jorge ; Wang, Lin ; Zhang, Bingzhi ; Pirozzi, Gianluca ; Sutherland, E Rand ; Evans, Robert R ; Joish, Vijay N ; Eckert, Laurent ; Graham, Neil M H ; Stahl, Neil ; Yancopoulos, George D ; Louis-Tisserand, Mariana ; Teper, Ariel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_18027836753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Asthma</topic><topic>Clinical trials</topic><topic>Comorbidity</topic><topic>Cytokines</topic><topic>Drug therapy</topic><topic>Steroids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wenzel, Sally</creatorcontrib><creatorcontrib>Castro, Mario</creatorcontrib><creatorcontrib>Corren, Jonathan</creatorcontrib><creatorcontrib>Maspero, Jorge</creatorcontrib><creatorcontrib>Wang, Lin</creatorcontrib><creatorcontrib>Zhang, Bingzhi</creatorcontrib><creatorcontrib>Pirozzi, Gianluca</creatorcontrib><creatorcontrib>Sutherland, E Rand</creatorcontrib><creatorcontrib>Evans, Robert R</creatorcontrib><creatorcontrib>Joish, Vijay N</creatorcontrib><creatorcontrib>Eckert, Laurent</creatorcontrib><creatorcontrib>Graham, Neil M H</creatorcontrib><creatorcontrib>Stahl, Neil</creatorcontrib><creatorcontrib>Yancopoulos, George D</creatorcontrib><creatorcontrib>Louis-Tisserand, Mariana</creatorcontrib><creatorcontrib>Teper, Ariel</creatorcontrib><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News &amp; ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database (ProQuest)</collection><collection>ProQuest Research Library</collection><collection>ProQuest Science Journals</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wenzel, Sally</au><au>Castro, Mario</au><au>Corren, Jonathan</au><au>Maspero, Jorge</au><au>Wang, Lin</au><au>Zhang, Bingzhi</au><au>Pirozzi, Gianluca</au><au>Sutherland, E Rand</au><au>Evans, Robert R</au><au>Joish, Vijay N</au><au>Eckert, Laurent</au><au>Graham, Neil M H</au><au>Stahl, Neil</au><au>Yancopoulos, George D</au><au>Louis-Tisserand, Mariana</au><au>Teper, Ariel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting [beta]2agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial</atitle><jtitle>The Lancet (British edition)</jtitle><date>2016-07-02</date><risdate>2016</risdate><volume>388</volume><issue>10039</issue><spage>31</spage><pages>31-</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody, inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated inflammation. Adults with uncontrolled persistent asthma who are receiving medium-to-high-dose inhaled corticosteroids plus a long-acting β2agonist require additional treatment options as add-on therapy. We aimed to assess the efficacy and safety of dupilumab as add-on therapy in patients with uncontrolled persistent asthma on medium-to-high-dose inhaled corticosteroids plus a long-acting β2agonist, irrespective of baseline eosinophil count. Methods We did this randomised, double-blind, placebo-controlled, parallel-group, pivotal phase 2b clinical trial at 174 study sites across 16 countries or regions. Adults (aged &gt;=18 years) with an asthma diagnosis for 12 months or more based on the Global Initiative for Asthma 2009 Guidelines receiving treatment with medium-to-high-dose inhaled corticosteroids plus a long-acting β2agonist were eligible for participation. Patients were randomly assigned (1:1:1:1:1) to receive subcutaneous dupilumab 200 mg or 300 mg every 2 weeks or every 4 weeks, or placebo, over a 24-week period. The primary endpoint was change from baseline at week 12 in forced expiratory volume in 1 s (FEV1in L) in patients with baseline blood eosinophil counts of at least 300 eosinophils per μL assessed in the intention-to-treat population. Safety outcomes were assessed in all patients that received at least one dose or part of a dose of study drug. This trial is registered atClinicalTrials.gov, numberNCT01854047, and with the EU Clinical Trials Register, EudraCT number 2013-000856-16. Findings 769 patients (158 in the placebo group and 611 in the dupilumab groups) received at least one dose of study drug. In the subgroup with at least 300 eosinophils per μL, the greatest increases (200 mg every 2 weeks, p=0·0008; 300 mg every 2 weeks, p=0·0063) in FEV1compared with placebo were observed at week 12 with doses every 2 weeks in the 300 mg group (mean change 0·39 L [SE 0·05]; mean difference 0·21 [95% CI 0·06-0·36; p=0·0063]) and in the 200 mg group (mean change 0·43 L [SE 0·05]; mean difference 0·26 [0·11-0·40; p=0·0008]) compared with placebo (0·18 L [SE 0·05]). Similar significant increases were observed in the overall population and in the fewer than 300 eosinophils per μL subgroup (overall population: 200 mg every 2 weeks, p&lt;0·0001; 300 mg every 2 weeks, p&lt;0·0001; &lt;300 eosinophils per μL: 200 mg every 2 weeks, p=0·0034; 300 mg every 2 weeks, p=0·0086), and were maintained to week 24. Likewise, dupilumab every 2 weeks produced the greatest reductions in annualised rates of exacerbation in the overall population (70-70·5%), the subgroup with at least 300 eosinophils per μL (71·2-80·7%), and the subgroup with fewer than 300 eosinophils per μL (59·9-67·6%). The most common adverse events with dupilumab compared with placebo were upper respiratory tract infections (33-41%vs35%) and injection-site reactions (13-26%vs13%). Interpretation Dupilumab increased lung function and reduced severe exacerbations in patients with uncontrolled persistent asthma irrespective of baseline eosinophil count and had a favourable safety profile, and hence in addition to inhaled corticosteroids plus long-acting β2-agonist therapy could improve the lives of patients with uncontrolled persistent asthma compared with standard therapy alone. Funding Sanofi-Genzyme and Regeneron Pharmaceuticals.</abstract><cop>London</cop><pub>Elsevier Limited</pub><doi>10.1016/S0140-6736(16)30307-5</doi></addata></record>
fulltext fulltext
identifier ISSN: 0140-6736
ispartof The Lancet (British edition), 2016-07, Vol.388 (10039), p.31
issn 0140-6736
1474-547X
language eng
recordid cdi_proquest_journals_1802783675
source Elsevier
subjects Asthma
Clinical trials
Comorbidity
Cytokines
Drug therapy
Steroids
title Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting [beta]2agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-23T02%3A29%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dupilumab%20efficacy%20and%20safety%20in%20adults%20with%20uncontrolled%20persistent%20asthma%20despite%20use%20of%20medium-to-high-dose%20inhaled%20corticosteroids%20plus%20a%20long-acting%20%5Bbeta%5D2agonist:%20a%20randomised%20double-blind%20placebo-controlled%20pivotal%20phase%202b%20dose-ranging%20trial&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Wenzel,%20Sally&rft.date=2016-07-02&rft.volume=388&rft.issue=10039&rft.spage=31&rft.pages=31-&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(16)30307-5&rft_dat=%3Cproquest%3E4113367381%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_18027836753%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1802783675&rft_id=info:pmid/&rfr_iscdi=true